Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The impact of the drug price revision, the反動 from sales to wholesalers being brought forward at the end of the previous fiscal year, slower new purchases of existing products following the announcement that the new product had obtained certification, higher energy and raw material costs due to the weaker yen, higher personnel expenses, and increased research and development expenses.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥15,821 million (YoY -0.7%) |
| Operating profit | ¥-696 million |
| Ordinary income | ¥-684 million |
| Profit attributable to owners of the parent | ¥-512 million |
| Net income per share | -¥141.57 |
| Equity ratio | End of the current fiscal period 38.7 / End of previous period 39 |
| Total assets | ¥48,801 million |
| Net assets | ¥18,884 million |
| Cash flows from operating activities | ¥-1,149 million |
| Cash flows from investing activities | ¥-579 million |
| Cash flows from financing activities | ¥679 million |
| Cash and cash equivalents at end of period | ¥4,276 million |
| Full-year earnings forecast | Net Sales ¥35,000 million (YoY +5.8%) / Operating profit ¥250 million (YoY +39.0%) / Ordinary income ¥100 million (YoY -56.1%) / Net income ¥60 million (YoY -69.7%) |
| Annual Dividend Forecast | 50 Yen → 50 Yen（0.0%） |
| Segment revenue | Pharmaceuticals Business ¥15,224 million (YoY -0.8%), Other ¥596 million (YoY +3.3%) |
| Segment profit | Pharmaceuticals Business ¥-687 million, Other ¥-9 million |
| Depreciation and amortization | ¥791 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities － / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | None |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 4,261,420 Shares |
| Treasury Shares at Period-End | 639,174 Shares |
| Factors Behind Changes in Business Performance | The impact of the drug price revision, the反動 from sales to wholesalers being brought forward at the end of the previous fiscal year, slower new purchases of existing products following the announcement that the new product had obtained certification, higher energy and raw material costs due to the weaker yen, higher personnel expenses, and increased research and development expenses. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The impact of the drug price revision, the反動 from sales to wholesalers being brought forward at the end of the previous fiscal year, slower new purchases of existing products following the announcement that the new product had obtained certification, higher energy and raw material costs due to the weaker yen, higher personnel expenses, and increased research and development expenses.